DIAGNOS Inc. (CVE:ADK – Get Free Report) dropped 4.5% on Monday. The company traded as low as C$0.31 and last traded at C$0.32. Approximately 106,000 shares traded hands during trading, a decline of 53% from the average session volume of 223,863 shares. The stock had previously closed at C$0.33.
DIAGNOS Stock Performance
The firm has a market capitalization of C$38.13 million, a price-to-earnings ratio of -7.88 and a beta of 0.05. The company has a fifty day moving average of C$0.42 and a two-hundred day moving average of C$0.31. The company has a debt-to-equity ratio of 204.05, a quick ratio of 0.68 and a current ratio of 1.49.
Insider Buying and Selling at DIAGNOS
In other DIAGNOS news, Director Robert Dunn bought 105,000 shares of DIAGNOS stock in a transaction dated Friday, August 28th. The stock was bought at an average price of C$0.48 per share, with a total value of C$50,400.00. Following the completion of the transaction, the director owned 2,679,920 shares in the company, valued at C$1,286,361.60. The trade was a 4.08% increase in their position. Corporate insiders own 16.81% of the company’s stock.
About DIAGNOS
DIAGNOS Inc. provides software-based services primarily in Canada, the United States, Colombia, Spain, Mexico, Saudi Arabia, and Costa Rica. The company offers healthcare services through Computer Assisted Retina Analysis, a web-based software tool that assists healthcare professionals for the detection of diabetic retinopathy; and allows eye care specialist to visualize both normal retinal landmarks and pathological changes. It also provides various consulting services in the fields of data analysis and artificial intelligence.
Further Reading
- Five stocks we like better than DIAGNOS
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Receive News & Ratings for DIAGNOS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DIAGNOS and related companies with MarketBeat.com's FREE daily email newsletter.
